CN108720018A - A kind of liver health care composition and its methods and applications containing curcumin - Google Patents
A kind of liver health care composition and its methods and applications containing curcumin Download PDFInfo
- Publication number
- CN108720018A CN108720018A CN201810678769.7A CN201810678769A CN108720018A CN 108720018 A CN108720018 A CN 108720018A CN 201810678769 A CN201810678769 A CN 201810678769A CN 108720018 A CN108720018 A CN 108720018A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- liver
- health care
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
The present invention relates to a kind of liver health care composition containing curcumin and its applications, and active constituent is by curcumin, chitosan oligosaccharide, black pepper, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin C, vitamin E, inositol raw material composition, the composition have effects of relieving alcoholism and protecting liver.The characteristics of present composition has definite ingredients, is formed with a variety of different effective substances, plays effects of relieving alcoholism and protecting liver using different requirement material effect principles and target spot, has taking dose small, integration of drinking and medicinal herbs is a kind of safely and effectively Antialcoholic liver-protecting food；It is demonstrated experimentally that the more single curcumin of the present composition, chitosan oligosaccharide, vitamin have stronger Antialcoholic liver-protecting activity.The characteristics of embodying compound synergistic effect can be used for preparing drug, health food with effects of relieving alcoholism and protecting liver.
Description
Technical field
The present invention relates to field of food health care, and in particular to a kind of curcumin composition of Antialcoholic liver-protecting.
Background technology
China has long culture of drinking, and wine infiltration is in entire 5,000 years civilized histories of China, in life in china
All occupy important position in living, work.Currently, as standard of living increasingly improves, the demand of various drinks increases therewith
Add, while the ratio of wine-head is also in rising trend, the alcoholic liver disease thereby resulted in also increases year by year therewith, threatens existing
For the health or even life of people." how can drink to one's heart's content and relieving alcoholism and protecting liver, escort for the health of oneself？" this
It is the target that many people pursue.It is one of the important channel for realizing this target to carry out Antialcoholic liver-protecting using natural products.
With the East Asia other countries for drinking traditional, curcumin has been effectively applied the exploitation in disintoxicating product.Ginger
Flavine [curcumin, 1,7- bis- (4- hydroxy-5-methyls oxygroup) phenyl -1,6- heptadiene 3,5- diketone] is from zingiber
The polyphenols extracted in Huang and turmeric play the most important active constituent of pharmacological action, and chemical constitution is shown in formula 1.Greatly
Amount scientific investigations showed that, except curcumin there is anti-oxidant, anti-inflammatory more, antiviral and antitumor etc. to plant a variety of physiological activity, and also
Alcohol induced Oxidative Damage in Liver can be effectively reduced, the remarkable result with Antialcoholic liver-protecting.
The chemical constitution of 1 curcumin of formula
Chitosan oligosaccharide (Chitooligosaccharides, COS) refers to low point of 2-10 Glucosamine unit composition
The water-soluble oligosaccharides of son amount, it is changed oligosaccharides of the chitosan through water-soluble low molecular weight made of enzyme degradation or chemical degradation
It learns structure and sees formula 2.The study found that chitosan oligosaccharide, which removes to have, adjusts immune, antitumor, anti-oxidant, reducing blood sugar and blood fat isoreactivity
Outside, also have the function of strengthening alcohol dehydrogenase, aldehyde dehydrogenase activity, to obtain the oxidation of ethanol in alcohol user liver
Acetaldehyde, and further by oxidation of acetaldehyde at CO2With H2O alleviates damage of the ethyl alcohol to liver, plays liver protection effect.
The chemical structural formula (n≤8) of 2 chitosan oligosaccharide of formula
Invention content
The purpose of the present invention is to provide a kind of curcumin compositions of Antialcoholic liver-protecting, can not only improve a large amount of drinks
Hepatic injury caused by alcohol accumulation after drinking, can also be relieved the symptom that mouthfeel tongue is dry after drinking, have good prevention and control
Therapeutic effect.
To achieve the above object, one aspect of the present invention provides the following technical solutions：A kind of liver health care composition, activity
Ingredient is by curcumin, chitosan oligosaccharide, black pepper, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin C, dimension life
Plain E, inositol raw material composition.
Preferably, liver health care composition is made of the raw material of following weight parts：10-200 parts of curcumin, chitosan oligosaccharide 10-
300 parts, 5-50 parts of black pepper, 1-10 parts of vitamin B1,1-10 parts of vitamin B2,1-10 parts of vitamin B3, vitamin B6
1-10 parts, 1-20 parts of vitamin C, 1-50 parts of vitamin E, 1-20 parts of inositol.
Preferably, the source of the curcumin includes turmeric.
Preferably, the chitosan oligosaccharide is prepared through enzyme process, polymerization scope 2-20.
Preferably, the composition is mixed with other auxiliary materials, dosage form include soft capsule, hard capsule, tablet, granule,
Oral agents, beverage, jelly, candy or soft sweets.
Another aspect of the present invention provides the preparation method of above-mentioned liver health care composition, by the raw material proportionally into
The processing of row physical mixed is to get to the liver health care composition.
Further aspect of the present invention provides the application of above-mentioned liver health care composition, is used for health food.
Preferably, the health food includes functional food.
Curcumin and chitosan oligosaccharide are the natural products for having sobering up and liver protecting functions, but protect liver mechanism is not quite similar, this hair
The liver health care composition of bright offer contains curcumin and chitosan oligosaccharide, and collaboration liver protection effect can be embodied in the presence of the two is common,
To improve protect liver effect；And both there are other health actives therefore, with curcumin and chitosan oligosaccharide be it is main effectively at
Point, novel effective relieving alcoholism and protecting liver product is developed, market prospects are boundless.
Specific implementation mode
In order to make content of the present invention easily facilitate understanding, With reference to embodiment to of the present invention
Technical solution further instruction, but the invention is not restricted to this.
Embodiment 1
Liver health care composition containing curcumin, by weight percentage, including following component：20 parts of curcumin, chitosan oligosaccharide
(DP2-8) 40 parts, 3 parts of black pepper, vitamin B11 part, 2 parts of vitamin B2,2 parts of vitamin B3,1 part of vitamin B6, dimension
Raw 5 parts of element C, 4 parts of vitamin E, 1 part of inositol.
Embodiment 2
Liver health care composition containing curcumin, by weight percentage, including following component：25 parts of curcumin, chitosan oligosaccharide
(DP2-8) 40 parts, 5 parts of black pepper .5 parts of vitaminB10,1 part of vitamin B2,1 part of vitamin B3,1 part of vitamin B6,
5 parts of vitamin C, 4 parts of vitamin E, 1 part of inositol.
Embodiment 3
Liver health care composition containing curcumin, by weight percentage, including following component：0 part of bisdemethoxycurcumin, chitosan oligosaccharide
(DP2-8) 40 parts, 5 parts of black pepper, vitamin B11 part, 2 parts of vitamin B2,2 parts of vitamin B3,1 part of vitamin B6, dimension
Raw 5 parts of element C, 4 parts of vitamin E, 1 part of inositol.
Embodiment 4
Liver health care composition containing curcumin, by weight percentage, including following component：5 parts of bisdemethoxycurcumin, chitosan oligosaccharide
(DP2-8) 40 parts, 5 parts of black pepper, vitamin B11 part, 2 parts of vitamin B2,2 parts of vitamin B3,1 part of vitamin B6, dimension
Raw 5 parts of element C, 4 parts of vitamin E, 1 part of inositol.
Embodiment 5：
Liver health care composition containing curcumin, by weight percentage, including following component：40 parts of curcumin, chitosan oligosaccharide
(DP2-8) 40 parts, 5 parts of black pepper, vitamin B12 part, 2 parts of vitamin B2,2 parts of vitamin B3,2 parts of vitamin B6, dimension life
5 parts of plain C, 4 parts of vitamin E, 1 part of inositol.
In order to confirm the effect of the present composition, using the proportioning of embodiment 1-5 by common process, i.e. physics is mixed
It closes, the liver health care composition containing curcumin is made, be respectively designated as J1, J2, J3, J4 and J5, resulting dosage forms carry out for pulvis
Zoopery, it is specific as follows.
SPF grades of SD rats are selected, male, weight 180-220g, standard environment adaptability is raised 1 week, and normal drink is given
Food.Every batch of animal is randomly divided into 9 groups, including Normal group, model control group, single medicine group and test group (table by weight
1), every group 8.Fasting 6h before the daily gavage of each group, in addition to normally organizing equivalent with physiological saline gavage, remaining each group is with second
Alcohol gavage, 5g/kg, continuous 5d (1 time/d), single medicine each group, experiment each group after ethyl alcohol gavage 1h again by table 1 give it is different at
Point gavage, 200mg/kg by whole rat anesthesias and are put to death after last ethyl alcohol gavage and fasting 6h, and abdominal aortic blood is surveyed
It is horizontal to determine rat blood serum glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminease (AST), total cholesterol (TC), triglycerides (TG).Take liver
It is preserved under lobus dexter about 1g hepatic tissue liquid nitrogen, and makes 10% liver homogenate and measure SOD, GSH-PX activity, MDA contents.Using
The processing of SPSS11.5 statistical softwares, test data indicate that measurement data uses one-way analysis of variance, compares between two groups with x ± s
It is examined compared with using LSD methods.Ranked data otherness is measured carries out statistical procedures using rank sum test.
Test group is arranged in table 1
Influence to alcoholic liver injury in rats Serum ALT, AST, TC, TG level the results are shown in Table 2.
The different single medicine groups of table 2, test group are to influence (n=9, the x of rat blood serum ALT, AST, TC, TG level2s)
Note：Compared with Normal group：P < 0.05,P < 0.01；Compared with model control group：* P < 0.05, * *
P < 0.01.
Compared with Normal group, model control group serum alt, AST activity obviously increase (P < 0.05) TC, TG increasings
High unobvious.Compared with model control group, experiment each group, single medicine each group make ALT activity significantly reduce P < 0.05), experiment
Each group reduces ALT active effects and is better than single medicine each group.Combining J4, J5 activity conspicuousness reduces P < 0.05).Reduction Serum ALT,
The activity of AST illustrates that drug has protective effect to rat acute alcoholic liver injury.Each group has no significant effect TC, TG.
Influence to alcoholic liver injury in rats liver homogenate MDA, GSH-PX activity, SOD contents:
Alcohol can cause mouse liver MDA contents significantly to increase, GSH-PX enzymes, SOD activity is caused to significantly reduce, and this
Inventive composition can significantly reduce MDA contents, can significantly increase GSH-PX enzymes, SOD activity.It is shown in Table 3.
The different single medicine groups of table 3, test group active, SOD contents influence (n=9, x to rat liver homogenate MDA, GSH-PX
±s)
Note：Compared with Normal group：P < 0.05,P < 0.01；Compared with model control group：* P < 0.05,
* P < 0.01
Composite reagent compares independent medication, can be relieved acute alcohol-induced hepatic injury.Composite reagent is to acute alcohol
Property hepatic injury have significant protective effect, can mitigate lipid peroxidation injury of the alcohol to liver, reduce serum transaminase and live
Property, improve the Histopathologic change of liver.Its mechanism of action may be by, to anti-oxidation stress, mitigating alcohol to liver cell
Direct detrimental effect, to play the role of protect liver cell, improve liver function.Wherein combination J4, J5 effect is especially aobvious
It writes.
Claims (8)
1. a kind of liver health care composition, it is characterised in that：Active constituent is by curcumin, chitosan oligosaccharide, black pepper, vitamin B1,
Vitamin B2, vitamin B3, vitamin B6, vitamin C, vitamin E, inositol raw material composition.
2. liver health care composition according to claim 1, which is characterized in that be made of the raw material of following weight parts：Ginger
10-200 parts of flavine, 10-300 parts of chitosan oligosaccharide, 5-50 parts of black pepper, 1-10 parts of vitamin B1,1-10 parts of vitamin B2, dimension life
Plain B3 1-10 parts, 1-10 parts of vitamin B6,1-20 parts of vitamin C, 1-50 parts of vitamin E, 1-20 parts of inositol.
3. liver health care composition according to claim 1 or 2, which is characterized in that the source of the curcumin includes ginger
It is yellow.
4. liver health care composition according to claim 1, which is characterized in that prepared by the chitosan oligosaccharide enzyme process, the degree of polymerization
Range 2-20.
5. liver health care composition according to claim 1, which is characterized in that the composition is mixed with other auxiliary materials, agent
Type includes soft capsule, hard capsule, tablet, granule, oral agents, beverage, jelly, candy or soft sweets.
6. the preparation method of liver health care composition described in claim 1-4 any one, which is characterized in that press the raw material
Physical mixed processing is carried out to get to the liver health care composition according to ratio.
7. the application of liver health care composition described in claim 1-4 any one, which is characterized in that be used for health food.
8. application according to claim 7, the health food includes functional food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810678769.7A CN108720018A (en) | 2018-06-27 | 2018-06-27 | A kind of liver health care composition and its methods and applications containing curcumin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810678769.7A CN108720018A (en) | 2018-06-27 | 2018-06-27 | A kind of liver health care composition and its methods and applications containing curcumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108720018A true CN108720018A (en) | 2018-11-02 |
Family
ID=63931146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810678769.7A Pending CN108720018A (en) | 2018-06-27 | 2018-06-27 | A kind of liver health care composition and its methods and applications containing curcumin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108720018A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110742897A (en) * | 2019-12-04 | 2020-02-04 | 山东陆海蓝圣生物科技股份有限公司 | Chitosan oligosaccharide and curcumin compound and application thereof |
| CN111357910A (en) * | 2020-04-20 | 2020-07-03 | 江苏慧博生物科技有限公司 | Turmeric and pepper solid beverage and preparation method thereof |
| CN112155213A (en) * | 2020-09-30 | 2021-01-01 | 迪沙药业集团有限公司 | Composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1478532A (en) * | 2003-07-11 | 2004-03-03 | 诸暨永隆山生物科技工程有限公司 | Sobering and liver protecting liquid product and its production method |
| CA2732635A1 (en) * | 2008-07-31 | 2010-02-04 | Santosh Kumar Kar | Curcumin nanoparticles and methods of producing the same |
| CN103535742A (en) * | 2013-09-27 | 2014-01-29 | 应博 | Anti-alcohol liver protection composition |
| CN104382893A (en) * | 2014-10-24 | 2015-03-04 | 青岛科技大学 | Soft capsule adopting VE, VC and curcumin as main medicine components |
| CN104489698A (en) * | 2014-12-02 | 2015-04-08 | 汤臣倍健股份有限公司 | Composition, application and health product |
| CN105232588A (en) * | 2015-11-13 | 2016-01-13 | 青岛明月海藻集团有限公司 | Health-care food with effect of protecting alcoholic liver injury and preparation method |
| CN106344603A (en) * | 2016-08-05 | 2017-01-25 | 青岛壳寡糖生物科技有限公司 | Application of chitosan oligosaccharide in use of alcoholism relieving and liver protecting |
| CN106692189A (en) * | 2017-01-25 | 2017-05-24 | 中国科学院化学研究所 | Composition capable of protecting liver |
| CN107156849A (en) * | 2017-07-12 | 2017-09-15 | 广州若晖生物科技有限公司 | A kind of joint care composition and its application containing curcumin |
-
2018
- 2018-06-27 CN CN201810678769.7A patent/CN108720018A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1478532A (en) * | 2003-07-11 | 2004-03-03 | 诸暨永隆山生物科技工程有限公司 | Sobering and liver protecting liquid product and its production method |
| CA2732635A1 (en) * | 2008-07-31 | 2010-02-04 | Santosh Kumar Kar | Curcumin nanoparticles and methods of producing the same |
| CN103535742A (en) * | 2013-09-27 | 2014-01-29 | 应博 | Anti-alcohol liver protection composition |
| CN104382893A (en) * | 2014-10-24 | 2015-03-04 | 青岛科技大学 | Soft capsule adopting VE, VC and curcumin as main medicine components |
| CN104489698A (en) * | 2014-12-02 | 2015-04-08 | 汤臣倍健股份有限公司 | Composition, application and health product |
| CN105232588A (en) * | 2015-11-13 | 2016-01-13 | 青岛明月海藻集团有限公司 | Health-care food with effect of protecting alcoholic liver injury and preparation method |
| CN106344603A (en) * | 2016-08-05 | 2017-01-25 | 青岛壳寡糖生物科技有限公司 | Application of chitosan oligosaccharide in use of alcoholism relieving and liver protecting |
| CN106692189A (en) * | 2017-01-25 | 2017-05-24 | 中国科学院化学研究所 | Composition capable of protecting liver |
| CN107156849A (en) * | 2017-07-12 | 2017-09-15 | 广州若晖生物科技有限公司 | A kind of joint care composition and its application containing curcumin |
Non-Patent Citations (2)
| Title |
|---|
| 刘利萍等: ""姜黄素协同氨基葡萄糖对小鼠急性酒精性肝损伤的保护作用"", 《中国新药杂志》 * |
| 孙涛等: "《国医年鉴（2017卷）》", 31 May 2017, 中医古籍出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110742897A (en) * | 2019-12-04 | 2020-02-04 | 山东陆海蓝圣生物科技股份有限公司 | Chitosan oligosaccharide and curcumin compound and application thereof |
| CN111357910A (en) * | 2020-04-20 | 2020-07-03 | 江苏慧博生物科技有限公司 | Turmeric and pepper solid beverage and preparation method thereof |
| CN112155213A (en) * | 2020-09-30 | 2021-01-01 | 迪沙药业集团有限公司 | Composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mitra et al. | Prospective multifunctional roles and pharmacological potential of dietary flavonoid narirutin | |
| Kifayatullah et al. | Evaluation of the acute and sub-acute toxicity of the ethanolic extract of Pericampylus glaucus (Lam.) Merr. in BALB/c mice | |
| Mertens-Talcott et al. | Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers | |
| Thakur et al. | Momordica balsamina: a medicinal and neutraceutical plant for health care management | |
| Zarei et al. | A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. | |
| Gbadamosi et al. | Nutritional composition of ten ethnobotanicals used for the treatment of anaemia in Southwest Nigeria | |
| US20140010899A1 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
| Khan et al. | Phytochemical and pharmacological properties on Citrus limetta (Mosambi) | |
| Olivier et al. | Annickia affinis and A. chlorantha (Enantia chlorantha)–a review of two closely related medicinal plants from tropical Africa | |
| Shahwar et al. | Hypoglycemic Activity of Ruellia tuberosa Linn (Acanthaceae) in Normal and Alloxan-Induced Diabetic Rabbits: Hypoglycemic Activity of Ruellia tuberosa Linn | |
| Zohrameena et al. | Medicinal uses & pharmacological activity of Tamarindus indica | |
| CN108720018A (en) | A kind of liver health care composition and its methods and applications containing curcumin | |
| Jimmy | Coleus aromaticus Benth.: an update on its bioactive constituents and medicinal properties | |
| WO2019017603A2 (en) | Composition for improving hangovers containing trapa japonica flerow extract and curcumin as active ingredient | |
| Rahiman et al. | Oleuropein and oleic acid: A novel emerging dietary target for human chronic diseases | |
| Ita et al. | Acetaminophen induced hepatic toxicity: protective role of Ageratum conyzoides | |
| Lim | Opuntia ficus-indica | |
| Kotue et al. | Ethnobotanicals usages in the management of sickle cell disease (SDC) in some localities of Cameroon | |
| El-Hadary | Antioxidant and hypoglycemic activity of doum fruit (hyphaene thebaica. L) extracts on diabetic albino rats | |
| Lim et al. | Cydonia oblonga | |
| KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
| El-Sherif et al. | Comparative Study for Group of Herbs VS. Glucophage Drug as Used for Obese Male Albino Rats | |
| Sari et al. | Overview of traditional use, phytochemical and pharmacological activities of cucumber (Cucumis sativus L.) | |
| González-Stuart | Multifaceted therapeutic value of roselle (Hibiscus sabdariffa L.–Malvaceae) | |
| Hadi et al. | Beneficial effects of gourds in health and diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181102 |